{"id":13912,"date":"2024-12-03T11:18:02","date_gmt":"2024-12-03T19:18:02","guid":{"rendered":"https:\/\/depts.washington.edu\/diabetes\/?p=13912"},"modified":"2024-12-03T11:18:02","modified_gmt":"2024-12-03T19:18:02","slug":"ada-warns-against-using-compounded-glp-1-ra-drugs","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/diabetes\/ada-warns-against-using-compounded-glp-1-ra-drugs\/","title":{"rendered":"ADA warns against using compounded GLP-1 RA drugs"},"content":{"rendered":"<section class=\"kc-elm kc-css-31325 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-558992 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-459427 kc_text_block\"><p>The American Diabetes Association published a statement in its journal <a href=\"https:\/\/diabetesjournals.org\/care\/article\/doi\/10.2337\/dci24-0091\/157478\/Compounded-GLP-1-and-Dual-GIP-GLP-1-Receptor\">Diabetes Care<\/a> advising against the use of compounded GLP-1 RA and dual GIP\/GLP-1 RA medications due to concerns about safety, quality and effectiveness. The ADA recommended using only FDA-approved medications for managing type 2 diabetes, weight and other conditions. &#8220;Compounded GLP-1 RA and dual GIP\/GLP-1 RA products have been associated with clinically important dosing errors and adverse events,\" the statement said.<\/p>\n<p>Full Story: <a href=\"https:\/\/www.medscape.com\/viewarticle\/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf\">Medscape<\/a> (12\/3)\u00a0\u00a0<\/p>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<p><!-- \/wp:post-content --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-13912","post","type-post","status-publish","format-standard","hentry","category-diabetes-related-news"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/comments?post=13912"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13912\/revisions"}],"predecessor-version":[{"id":13913,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13912\/revisions\/13913"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/media?parent=13912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/categories?post=13912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/tags?post=13912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}